Abbott Has No Intentions to Sell Dx Businesses, Officials Say | GenomeWeb
WASHINGTON, DC (GenomeWeb News) - A year after an $8.1 billion agreement to sell two of its diagnostic divisions to General Electric fell apart, Abbott Laboratories has no intentions of getting rid of those divisions or any other parts of its diagnostics business, company officials said Tuesday at the annual meeting of the American Association for Clinical Chemistry.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.